Pharmaceuticals stock, reducing the price target from $1,185.00 to $1,150.00. Despite the decrease, the firm maintained its Overweight rating on the NASDAQ-listed company. According to InvestingPro ...
These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rezolute (RZLT – Research Report) and Pfizer (PFE – Research ...
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher Scientific Inc. , the world leader in serving science, today announced a 10-year virtual power purchasing agreement (VPPA) with international renewable energy developer X-ELIO designed ...
X-ELIO, a global leader in renewable energy, has signed a multi-buyer Power Purchase Agreement (PPA) with an Energize program ...
The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...
The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...
Collaboration is also unlocking extraordinary potential through the integration of advanced technologies. From harnessing ...
Innate Pharma (NASDAQ:IPHA – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based ...
We argue against selling Geron at current prices, citing strong market potential of imetelstat and Royalty Pharma deal ...
Join host Neil Lander as he welcomes Katy Rhynard, Associate Director of Laboratory Informatics at Gilead Sciences.